Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV9104 in High and Intermediate Risk Prostate Cancer
NCT02140138Phase 2Terminated
- Sponsor
- CureVac
- Start
- Jun 2014
- Primary completion
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CV9104 in prostate carcinoma (3 arms), sponsored by CureVac. Primary endpoint: Induction of antigen-specific cellular and humoral immune response. Started Jun 2014; status: terminated.
02
Drugs
CV9104
03
Conditions
prostate carcinoma
Beyond the preview
Go deeper on NCT02140138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140138.